Abstract
Insulin-like growth factors (IGFs) regulate cellular proliferation and death, and their bioactivity is controlled by IGF binding proteins (IGFBPs). Since IGFBP-2 is the major brain resident IGFBP, and we have demonstrated lithium-mediated changes in its mRNA and protein levels in neuronal cultures, we examined IGFBP-2 expression in prefrontal cortex postmortem brain tissue from subjects with mood disorders. We found decreased IGFBP-2 expression in bipolar disorder patients compared with controls; this was especially pronounced in subjects not treated with lithium. These results suggest a role for IGFBPs in the etiology and pharmacotherapy of mood disorders.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Analysis of Variance
-
Bipolar Disorder / drug therapy
-
Bipolar Disorder / metabolism*
-
Case-Control Studies
-
Depressive Disorder, Major / drug therapy
-
Depressive Disorder, Major / metabolism
-
Down-Regulation
-
Female
-
Humans
-
Insulin-Like Growth Factor Binding Protein 2 / drug effects
-
Insulin-Like Growth Factor Binding Protein 2 / genetics
-
Insulin-Like Growth Factor Binding Protein 2 / metabolism*
-
Lithium Compounds / therapeutic use*
-
Male
-
Matched-Pair Analysis
-
Middle Aged
-
Prefrontal Cortex / drug effects
-
Prefrontal Cortex / metabolism*
-
Prefrontal Cortex / physiopathology
-
RNA, Messenger / analysis
-
Reference Values
-
Statistics, Nonparametric
Substances
-
Insulin-Like Growth Factor Binding Protein 2
-
Lithium Compounds
-
RNA, Messenger